While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

Insomnia and other common sleep impacts in CSU improve with biologic medication ...

Corvus Pharmaceuticals soars on promising Phase 1 data for soquelitinib. But CRVS shares may not be able to sustain today's ...

The sizzle is the excitement about the hunt for the next big blockbuster, and the only one that anyone sees on the horizon is ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes Ceragon Networks, Celldex, ...

Sanofi (SAN:CA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:45 PM ESTCompany ParticipantsPaul Hudson - CEO & ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

For Tracy Owen, eczema was much more than dry skin. It came to dictate every aspect of her life, from ­relationships to how she dressed.

BofA Securities upgrades shares to Buy from Hold with an $860 price target, up sharply from $627.

In the trial, zumilokibart demonstrated: The only treatment-emergent adverse event (TEAE) observed in more than one patient was gastroesophageal reflux disease (GERD; 2 patients). There were no Grade ...

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.